查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
腫瘤浸潤淋巴球治療的全球市場:標的各適應症，各主要加入企業，各主要地區 - 產業趨勢世界預測(2023年～2035年)
市場調查報告書
商品編碼
1207466

腫瘤浸潤淋巴球治療的全球市場:標的各適應症，各主要加入企業，各主要地區 - 產業趨勢世界預測(2023年～2035年)

Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions : Industry Trends and Global Forecasts, 2023-2035
出版日期: | 出版商: Roots Analysis | 英文 315 Pages | 商品交期: 最快1-2個工作天內

價格

本報告提供全球腫瘤浸潤淋巴球治療市場相關調查，市場概要，以及標的各適應症，各主要加入企業，各主要地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 序文

第2章 摘要整理

第3章 簡介

  • 章概要
  • 癌症治療的柱子
  • 免疫療法概要
  • 癌症免疫療法的基礎
  • 癌症免疫療法的分類
  • T細胞免疫療法
  • 腫瘤浸潤淋巴球(TIL)為基礎的細胞療法
  • 主要的優點與障礙
  • 結束

第4章 腫瘤浸潤淋巴球治療:市場風景

  • 章概要
  • 腫瘤浸潤淋巴球治療:整體市場形勢
  • 腫瘤浸潤淋巴球治療:開發商的透視

第5章 臨床試驗分析

  • 章概要
  • 範圍與調查手法
  • 腫瘤浸潤淋巴球治療:臨床試驗的分析

第6章 主要意見領袖

第7章 腫瘤浸潤淋巴球治療簡介

第8章 夥伴關係和合作

第9章 資金籌措投資分析

第10章 專利分析

  • 章概要
  • 範圍與調查手法
  • 腫瘤浸潤淋巴球治療:專利分析

第11章 案例研究:細胞療法的製造

第12章 原價分析

  • 章概要
  • 細胞、基因治療的高額化的要素
  • T細胞免疫療法的定價模式
  • T細胞免疫療法的償付相關考慮事項

第13章 市場預測機會分析

第14章 企業簡介

  • 章概要
  • Cellectis
  • Cellular Biomedicine Group
  • Iovance Biotherapeutics
  • Lytix Biopharma
  • Phio Pharmaceuticals

第15章 結論

第16章 執行見解

第17章 附錄I:表格形式的資料

第18章 附錄II:公司及組織的清單

Product Code: RA100411

INTRODUCTION

Over the years, various studies have validated the successful use of tumor-infiltrating lymphocytes (TILs) in treating patients diagnosed with refractory diseases. TILs are a heterogeneous population of mononuclear lymphocytes that comprise of T-cells, B-cells, NK cells and macrophages isolated from the tumor. These lymphocytes selectively mediate the elimination of tumor cells. Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various solid tumors. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the TIL-based therapy market is likely to witness significant growth in the foreseen future.

SCOPE OF THE REPORT

The "Global TIL-based Therapy Market (2nd Edition), 2023-2035: Distribution by Target Indication (Melanoma, Head and Neck Carcinoma, Chronic Lymphocytic Leukemia, Sarcoma, Hepatocellular Carcinoma, Breast Cancer, Acute Myeloid Leukemia and Cervical Carcinoma), Key Players and Key Geographical Regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035" report features an extensive study of the current market landscape and future opportunity for the players focused on the development of TIL-based therapies. The report answers many key questions related to this domain.

Need for TIL-based Therapies for the Treatment of Various Types of Cancer

Modified tumor-infiltrating lymphocytes (TIL)-based interventions have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects. Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority (over conventional treatment options) of TIL-based therapies. Their tumor-cell killing efficiency is attributed to the fact that they are pre-sensitized to cancer specific antigens. Additionally, this emerging class of biologics is believed to possess the potential to cater to the unmet pharmacological needs, across both oncological and non-oncological disorders, even those where small molecule drugs have proven to be inadequate.

Current Market Landscape of TIL-based Therapies

Over 75 TIL immunotherapies are being evaluated across different stages of preclinical / clinical development, either as monotherapies or in combination with other drugs. Both industry and non-industry players have demonstrated keen interest in the development of novel TIL-based cell therapies. Further, melanoma emerged as the most popular target indication in this domain. More than 95% of the therapy candidates that are being developed to target a wide range of disease indications are autologous in nature.

Rising Interest in TIL-based Therapies

A growing interest in TIL-based therapies is reflected from the increase in the partnerships focused on R&D of such therapies. Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 2.7 billion, across 30 instances, since 2013. Further, in the last 10 years, close to 95 clinical trials evaluating TIL-based therapies have been registered across different geographies. Mostly driven by the need for effective treatment options for cancer, the TIL-based therapy pipeline is expected to steadily grow over the coming years. Moreover, clinical success is likely to draw in investments that are likely to support the ongoing and anticipated therapy development initiatives.

Market Size of the TIL-based Therapy Market

With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of 40% in the next decade. Specifically, in terms of target indication, the market is anticipated to be driven by therapies being developed to target melanoma and head and neck carcinoma. Additionally, close to 90% of the market is anticipated to be captured by players based in North America and Europe, in 2035. Overall, we are led to believe that the global TIL-based therapy market is poised to witness significant growth in the foreseen future.

Who are the Key Players in the TIL-based Therapy Market

Examples of key players engaged in this domain (which have also been captured in this report) include Bristol-Myers Squibb, CAR-T (Shanghai) Cell Biotechnology, Cellectis, Incyte Corporation, Instil Bio, Iovance Biotherapeutics, Lytix Biopharma, Phio Pharmaceuticals and Prometheus Laboratories.

The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:

  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of global TIL-based therapies market and its likely evolution in the mid-long term.
  • A general overview of TIL-based therapies in comparison to conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, and key attributes in the development of TIL-based therapies.
  • A detailed assessment of the overall market landscape of TIL-based therapies, based on several relevant parameters, such as type of developer (industry and non-industry), phase of development (preclinical, phase I, phase I/II, phase II, phase III and approved), therapeutic area (hematological cancer, solid tumor and others), key target indications (melanoma, ovarian cancer, cervical cancer, lung cancer, pancreatic cancer, sarcoma, breast cancer, squamous cell carcinoma, fallopian tube cancer, gastric cancer, head and neck squamous cell carcinoma and others), source of T-cells (autologous and allogeneic), route of administration (intravenous and hepatic arterial infusion), dosing frequency (single dose and multiple dose), target patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Further, the chapter also provides developer landscape of industry and non-industry players engaged in this domain.
  • An analysis of completed, ongoing, and planned clinical studies related to TIL-based therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, target patient segment, type of sponsor / collaborator, study design, most active players (in terms of number of registered trials), key focus areas and geography.
  • An insightful analysis highlighting the key opinion leaders (KOLs) in this domain, featuring an analysis of the various principal investigators of clinical trials related to TIL-based therapies, considering them to be KOLs, who are actively involved in R&D of TIL-based therapies. In addition, it compares the relative expertise of KOLs based on a proprietary scoring criterion with that of a third party.
  • Elaborate profiles of mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), a clinical development plan, and clinical trial results.
  • A detailed analysis of recent partnerships inked between several stakeholders engaged in this domain, covering R&D agreements, license agreements (specific to technology platforms and product candidates), manufacturing agreements, clinical trial collaborations and others.
  • An analysis of the funding and investments that have been made into companies having proprietary TIL-based products / technologies, including venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing.
  • An in-depth analysis of patents related to TIL-based therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted and patent applications), patent publication year, geographical distribution, type of player, Cooperative Patent Classification (CPC) symbols, emerging focus areas, leading players (in terms of number of patents), and patent benchmarking. In addition, it features a patent valuation analysis, which evaluates the qualitative and quantitative aspects of the patents.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a TIL-based therapy that is likely to be marketed in the coming years.
  • Elaborate profiles of the leading players in the domain of TIL-based therapies. Each company profile includes an overview of the developer and a brief description of the product portfolio specific to TIL-based therapies, the technology portfolio (if available), recent developments related to TIL-based therapies, and the manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

One of the key objectives of the report was to estimate the current opportunity and the future growth potential of TIL-based therapies over the coming decade. Based on several parameters, such as target consumer segments, region-specific adoption rates, and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of TIL-based therapies that are in the mid- to late stages of development. Additionally, it features market size projections for the overall TIL-based therapies market, wherein both the current and upcoming opportunity is segmented across target indication (melanoma, head and neck carcinoma, chronic lymphocytic leukemia, sarcoma, hepatocellular carcinoma, breast cancer, acute myeloid leukemia and cervical carcinoma), key players and key geographical regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base, and optimistic scenarios, which represent different tracks of the industry's evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED

Question 1: What is the growth rate of TIL-based therapy market?

Answer: The global TIL-based therapies market is expected to grow at a compound annual growth rate (CAGR) of 40% from 2023-2035.

Question 2: Which region has the highest growth rate in the TIL-based Therapies market?

Answer: Europe is growing at the highest CAGR, over the period 2023-2035.

Question 3: How many players are developing TIL-based Therapies?

Answer: Close to 30 industry and non-industry players are currently evaluating the potential of over 75 TIL-based therapies for the treatment of various oncological and non-oncological disorders.

Question 4: Which target indication is likely to cover the largest TIL-based therapy market share in 2035?

Answer: Melanoma is likely to capture the maximum share (51%) of the TIL-based therapy market in 2035.

Question 5: What is the partnership and collaboration trend in the TIL-based therapy domain?

Answer: Currently, R&D agreements, licensing agreements, and manufacturing agreements are the common types of partnerships inked by developers involved in the TIL-based therapy domain.

Question 6: What is the current IP landscape of TIL-based therapies market?

Answer: More than 70% of the filed patents were patent applications, while around 28% were granted patents. Of the total granted applications, more than 95% were filed in the US.

CHAPTER OUTLINES

Chapter 1: is a preface providing an introduction to the full report, TIL-based therapy market (2nd Edition), 2023-2035.

Chapter 2: provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the TIL-based therapy market in the short to mid-term and long term.

Chapter 3: provides a general overview of TIL-based therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, and key attributes in the development of TIL-based therapies.

Chapter 4: includes detailed assessment of the current market landscape of more than 75 TIL-based therapies that are currently approved or are in different stages of the development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (preclinical, phase I, phase I/II, phase II, phase III and approved), therapeutic area (hematological cancer, solid tumor and others), key target indications (melanoma, ovarian cancer, cervical cancer, lung cancer, pancreatic cancer, sarcoma, breast cancer, squamous cell carcinoma, fallopian tube cancer, gastric cancer, head and neck squamous cell carcinoma and others), source of T-cells (autologous and allogeneic), route of administration (intravenous and hepatic arterial infusion), dosing frequency (single dose and multiple dose), target patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized, and large) and location of headquarters (North America, Europe, and Asia Pacific).

Chapter 5: presents a detailed analysis of completed, ongoing, and planned clinical studies related to TIL-based therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, study design, most active players (in terms of number of registered trials), and geography.

Chapter 6: presents an analysis highlighting the key opinion leaders (KOLs) in this domain, featuring an analysis of the various principal investigators of clinical trials related to TIL-based therapies, considering them to be KOLs, who are actively involved in R&D of TIL-based therapies. In addition, it compares the relative expertise of KOLs based on a proprietary scoring criterion with that of a third party.

Chapter 7: provides detailed profiles of mid to late-stage TIL-based therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 8: features an analysis of the recent partnerships inked between several stakeholders engaged in this domain, covering R&D agreements, license agreements (specific to technology platforms and product candidates), manufacturing agreements, clinical trial collaborations and others, companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Chapter 9: provides details on the various funding and investments that have been made into companies having proprietary TIL-based products / technologies, including venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing. It includes a detailed analysis of the funding instances that have taken place in the period between 2013 to 2022, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 10: provides an in-depth analysis of patents related to TIL-based therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted and patent applications), patent publication year, geographical distribution, type of player, Cooperative Patent Classification (CPC) symbols, emerging focus areas, leading players (in terms of number of patents), and patent benchmarking. In addition, it features a patent valuation analysis, which evaluates the qualitative and quantitative aspects of the patents.

Chapter 11: provides case study on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. Additionally, it includes a detailed list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 12: highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their TIL-based therapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for TIL-based therapies.

Chapter 13: features an elaborate discussion on the future commercial opportunity offered by TIL-based therapies. It provides a comprehensive market forecast analysis for TIL-based products that are approved or are in phase I/II and phase II of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation, based on target indication (melanoma, head and neck carcinoma, chronic lymphocytic leukemia, sarcoma, hepatocellular carcinoma, breast cancer, acute myeloid leukemia and cervical carcinoma), key players, and key geographical regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World).

Chapter 14: includes brief company profiles of the leading players in the domain of TIL-based therapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to TIL-based therapies, technology portfolio (if available), recent developments related to TIL-based therapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 15: is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 16: is a collection of transcripts of interviews conducted with key stakeholders in the market.

Chapter 17: is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 18: is an appendix, which contains a list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Pillars of Cancer Therapy
  • 3.3. Overview of Immunotherapies
  • 3.4. Fundamentals of Cancer Immunotherapy
  • 3.5. Classification of Cancer Immunotherapies
    • 3.5.1. By Mechanism of Action
    • 3.5.2. By Type of Target
    • 3.5.3. By Approach
    • 3.5.4. By Product Class
  • 3.6. T-Cell Immunotherapies
    • 3.6.1. Historical Evolution
    • 3.6.2. Key Considerations for Developing T-Cell Immunotherapies
    • 3.6.3. Strategies Employed for the Redirection of T-Cells
    • 3.6.4. Manufacturing of Engineered T-Cells
    • 3.6.5. T-Cell Transduction and Transfection Methods
  • 3.7. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
    • 3.7.1. Development History
    • 3.7.2. Development of TILs Therapy
  • 3.8. Key Benefits and Roadblocks
  • 3.9. Concluding Remarks

4. TIL-BASED THERAPIES: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. TIL-based Therapies: Overall Market Landscape
    • 4.2.1. Analysis by Type of Developer
    • 4.2.2. Analysis by Phase of Development
    • 4.2.3. Analysis by Therapeutic Area
    • 4.2.4. Analysis by Key Target Indications
    • 4.2.5. Analysis by Source of T-Cells
    • 4.2.6. Analysis by Route of Administration
    • 4.2.7. Analysis by Dosing Frequency
    • 4.2.8. Analysis by Target Patient Segment
    • 4.2.9. Analysis by Type of Therapy
    • 4.2.10. Most Active Industry Players: Analysis by Number of TIL-based Therapies
    • 4.2.11. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies
  • 4.3. TIL-based Therapies: Overall Developer Landscape
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters

5. CLINICAL TRIAL ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Scope and Methodology
  • 5.3. TIL-based Therapies: Clinical Trial Analysis
    • 5.3.1. Analysis by Trial Registration Year
    • 5.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
    • 5.3.3. Analysis by Trial Status
    • 5.3.4. Analysis by Trial Registration Year and Trial Status
    • 5.3.5. Analysis by Trial Phase
    • 5.3.6. Analysis by Trial Phase and Enrolled Patient Population
    • 5.3.7. Analysis by Target Patient Segment
    • 5.3.8. Analysis by Type of Sponsor / Collaborator
    • 5.3.9. Analysis by Study Design
    • 5.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
    • 5.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
    • 5.3.12. Word Cloud Analysis: Emerging Focus Areas
    • 5.3.13. Analysis of Clinical Trials by Geography
    • 5.3.14. Analysis of Enrolled Patient Population by Geography

6. KEY OPINION LEADERS

  • 6.1. Chapter Overview
  • 6.2. Assumptions and Key Parameters
  • 6.3. Methodology
  • 6.4. TIL-based Therapies: Key Opinion Leaders
    • 6.4.1. Analysis by Type of Organization
    • 6.4.2. Analysis by Affiliated Organization
    • 6.4.3. Analysis by Qualification
    • 6.4.4. Analysis by Geographical Location of KOLs
    • 6.4.5. KOL Activeness versus KOL Strength
    • 6.4.6. Most Prominent KOLs: Analysis by RA score
    • 6.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

7. TIL-BASED THERAPY PROFILES

  • 7.1. Chapter Overview
  • 7.2. LN-144 / Lifileucel (Iovance Biotherapeutics)
    • 7.2.1. Therapy Overview
    • 7.2.2. Clinical Trial Information
    • 7.2.3. Clinical Trial Endpoints
    • 7.2.4. Clinical Trial Results
    • 7.2.5. Estimated Sales Revenues
  • 7.3. LN-145 (Iovance Biotherapeutics)
    • 7.3.1. Therapy Overview
    • 7.3.2. Clinical Trial Information
    • 7.3.3. Clinical Trial Endpoints
    • 7.3.4. Clinical Trial Results
    • 7.3.5. Estimated Sales Revenues
  • 7.4. ITIL-168 (Instil Bio)
    • 7.4.1. Therapy Overview
    • 7.4.2. Clinical Trial Information
    • 7.4.3. Clinical Trial Endpoints
    • 7.4.4. Clinical Trial Results
    • 7.4.5. Estimated Sales Revenues
  • 7.5. LTX-315 (Lytix Biopharma)
    • 7.5.1. Therapy Overview
    • 7.5.2. Clinical Trial Information
    • 7.5.3. Clinical Trial Endpoints
    • 7.5.4. Clinical Trial Results
    • 7.5.5. Estimated Sales Revenues

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. TIL-based Therapies: Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Year of Partnership and Type of Partnership
    • 8.3.4. Analysis by Type of Partner
    • 8.3.5. Most Popular Products: Analysis by Number of Partnerships
    • 8.3.6. Most Active Industry Players: Analysis by Number of Partnerships
    • 8.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
    • 8.3.8. Analysis by Geography
      • 8.3.8.1. Intercontinental and Intracontinental Agreements
      • 8.3.8.2. International and Local Deals

9. FUNDING AND INVESTMENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Type of Funding
  • 9.3. TIL-based Therapies: Funding and Investment Analysis
    • 9.3.1. Analysis by Year of Investment
    • 9.3.2. Analysis by Amount Invested
    • 9.3.3. Analysis by Type of Funding
    • 9.3.4. Analysis by Type of Investor
    • 9.3.5. Most Active Players: Analysis by Number of Instances
    • 9.3.6. Most Active Investors: Analysis by Amount Invested
    • 9.3.7. Analysis of Amount Invested by Geography
    • 9.3.8. Most Active Investors: Analysis by Number of Funding Instances

10. PATENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. TIL-based Therapies: Patent Analysis
    • 10.3.1. Analysis by Patent Publication Year
    • 10.3.2. Analysis By Patent Application Year
    • 10.3.3. Analysis by Geography
    • 10.3.4. Analysis by Type of Player
    • 10.3.5. Analysis by CPC Symbols
    • 10.3.6. Word Cloud Analysis: Emerging Focus Areas
    • 10.3.7. Leading Players: Analysis by Number of Patents
    • 10.3.8. TIL-based Therapies: Patent Benchmarking
    • 10.3.9. Analysis By Patent Characteristics
    • 10.3.10. TIL-based Therapies: Patent Valuation

11. CASE STUDY: CELL THERAPY MANUFACTURING

  • 11.1. Chapter Overview
  • 11.2. Overview of Cell Therapy Manufacturing
  • 11.3. Cell Therapy Manufacturing Models
    • 11.3.1. Centralized Manufacturing Model
    • 11.3.2. Decentralized Manufacturing Model
  • 11.4. Scalability of Cell Therapy Manufacturing Processes
    • 11.4.1. Scale-Up
    • 11.4.2. Scale-Out
  • 11.5. Types of Cell Therapy Manufacturers
  • 11.6. Key Challenges Related to Manufacturing of Cell Therapies
  • 11.7. Important Factors for Cell Therapy Manufacturing
    • 11.7.1. Characterization
    • 11.7.2. Cost of Goods
  • 11.8. Automation of Cell Therapy Manufacturing Process
  • 11.9. Cell Therapy Manufacturing Supply Chain
  • 11.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
  • 11.11. Regulatory Landscape
  • 11.12. Future Perspectives

12. COST PRICE ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Factors Contributing to the High Price of Cell / Gene Therapies
  • 12.3. Pricing Models for T-Cell Immunotherapies
    • 12.3.1. Based on Associated Costs
    • 12.3.2. Based on Availability of Competing Products
    • 12.3.3. Based on Patient Segment
    • 12.3.4. Based on Opinions of Industry Experts
  • 12.4. Reimbursement related Considerations for T-Cell Immunotherapies

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Scope and Limitations
  • 13.3. Key Assumptions and Forecast Methodology
  • 13.4. Global TIL-Based Therapies Market, 2022-2035
    • 13.4.1. TIL-based Therapies Market: Analysis by Target Indication
    • 13.4.2. TIL-based Therapies Market: Analysis by Key Players
    • 13.4.3. TIL-based Therapies Market: Analysis by Key Geographical Regions
    • 13.4.4. Product Wise Sales Forecast
      • 13.4.4.1. Lifileucel / LN-144 (Iovance Biotherapeutics)
        • 13.4.4.1.1. Sales Forecast (USD Million)
        • 13.4.4.1.2. Net Present Value (USD Million)
        • 13.4.4.1.3. Value Creation Analysis
      • 13.4.4.2. LN-145 (Iovance Biotherapeutics)
        • 13.4.4.2.1. Sales Forecast (USD Million)
        • 13.4.4.2.2. Net Present Value (USD Million)
        • 13.4.4.2.3. Value Creation Analysis
      • 13.4.4.3. LTX-315 and TILs (Lytix Biopharma)
        • 13.4.4.3.1. Sales Forecast (USD Million)
        • 13.4.4.3.2. Net Present Value (USD Million)
        • 13.4.4.3.3. Value Creation Analysis
      • 13.4.4.4. TILs (Prometheus Laboratories)
        • 13.4.4.4.1. Sales Forecast (USD Million)
        • 13.4.4.4.2. Net Present Value (USD Million)
        • 13.4.4.4.3. Value Creation Analysis
      • 13.4.4.5. Donor Lymphocyte Infusion (Incyte)
        • 13.4.4.5.1. Sales Forecast (USD Million)
        • 13.4.4.5.2. Net Present Value (USD Million)
        • 13.4.4.5.3. Value Creation Analysis
      • 13.4.4.6. ITIL-168 (Instil Bio)
        • 13.4.4.6.1. Sales Forecast (USD Million)
        • 13.4.4.6.2. Net Present Value (USD Million)
        • 13.4.4.6.3. Value Creation Analysis
      • 13.4.4.7. IOV-2001 (Iovance Biotherapeutics)
        • 13.4.4.7.1. Sales Forecast (USD Million)
        • 13.4.4.7.2. Net Present Value (USD Million)
        • 13.4.4.7.3. Value Creation Analysis
      • 13.4.4.8. TILs (CAR-T (Shanghai) Cell Biotechnology)
        • 13.4.4.8.1. Sales Forecast (USD Million)
        • 13.4.4.8.2. Net Present Value (USD Million)
        • 13.4.4.8.3. Value Creation Analysis
      • 13.4.4.9. TILs (Bristol-Myers Squibb)
        • 13.4.4.9.1. Sales Forecast (USD Million)
        • 13.4.4.9.2. Net Present Value (USD Million)
        • 13.4.4.9.3. Value Creation Analysis

14. COMPANY PROFILES

  • 14.1. Chapter Overview
  • 14.2. Cellectis
  • 14.3. Cellular Biomedicine Group
  • 14.4. Iovance Biotherapeutics
  • 14.5. Lytix Biopharma
  • 14.6. Phio Pharmaceuticals

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS

17. APPENDIX I: TABULATED DATA

18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF TABLES

  • Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
  • Table 3.2 FDA Approved Antibody-based Cancer Therapeutics
  • Table 3.3 Retroviral Vectors: Salient Features
  • Table 3.4 Lentiviral Vectors: Salient Features
  • Table 4.1 TIL-based Therapies: Clinical Pipeline
  • Table 4.2 TIL-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
  • Table 4.3 TIL-based Therapies: Preclinical Pipeline
  • Table 4.4 List of TIL-based Developers
  • Table 6.1 TIL-based Therapies: List of Principal Investigators
  • Table 7.1 TIL Cell Therapies: List of Therapies Profiled
  • Table 7.2 Therapy Profile: LN-144 (Iovance Biotherapeutics)
  • Table 7.3 LN-144: Clinical Trial Information
  • Table 7.4 LN-144: Clinical Trial Endpoints
  • Table 7.5 LN-144: Clinical Trial Results
  • Table 7.6 Therapy Profile: LN-145 (Iovance Biotherapeutics)
  • Table 7.7 LN-145: Clinical Trial Information
  • Table 7.8 LN-145: Clinical Trial Endpoints
  • Table 7.9 LN-145: Clinical Trial Results
  • Table 7.10 Therapy Profile: ITIL-168 (Instil Bio)
  • Table 7.11 ITIL-168: Clinical Trial Information
  • Table 7.12 ITIL-168: Clinical Trial Endpoints
  • Table 7.13 ITIL-168: Clinical Trial Results
  • Table 7.14 Therapy Profile: LTX-315 (Lytix Biopharma)
  • Table 7.15 LTX-315: Clinical Trial Information
  • Table 7.16 LTX-315: Clinical Trial Endpoints
  • Table 7.17 LTX-315: Clinical Trial Results
  • Table 8.1 List of Partnerships and Collaborations, 2005-2022
  • Table 9.1 List of Funding and Investments, 2007-2022
  • Table 9.2 Funding and Investment Analysis: Summary of Investments
  • Table 10.1 Patent Analysis: Prominent CPC Symbols
  • Table 10.2 Patent Analysis: Most Popular CPC Symbols
  • Table 10.3 Patent Analysis: List of Top CPC Symbols
  • Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 11.1 Assessment Strategies for Different Manufacturing Processes
  • Table 11.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
  • Table 11.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
  • Table 12.1 Price of Marketed Gene / Cell Therapies
  • Table 12.2 Price of Marketed Targeted Drugs
  • Table 12.3 TIL-based Therapies: Expert Opinions on Pricing
  • Table 12.4 TIL-based Therapies: Reimbursement Landscape
  • Table 13.1 TIL-based Therapies: List of Forecasted Molecules
  • Table 13.2 Lifileucel / LN-144 (Iovance Biotherapeutics): Net Present Value (USD Million)
  • Table 13.3 Lifileucel / LN-144 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
  • Table 13.4 LN-145 (Iovance Biotherapeutics): Net Present Value (USD Million)
  • Table 13.5 LN-145 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
  • Table 13.6 LTX-315 and TILs (Lytix Biopharma): Net Present Value (USD Million)
  • Table 13.7 LTX-315 and TILs (Lytix Biopharma): Value Creation Analysis (USD Million)
  • Table 13.8 TILs (Prometheus Laboratories): Net Present Value (USD Million)
  • Table 13.9 TILs (Prometheus Laboratories): Value Creation Analysis (USD Million)
  • Table 13.10 Donor Lymphocyte Infusion (Incyte): Net Present Value (USD Million)
  • Table 13.11 Donor Lymphocyte Infusion (Incyte): Value Creation Analysis (USD Million)
  • Table 13.12 ITIL-168 (Instil Bio): Net Present Value (USD Million)
  • Table 13.13 ITIL-168 (Instil Bio): Value Creation Analysis (USD Million)
  • Table 13.14 IOV-2001 (Iovance Biotherapeutics): Net Present Value (USD Million)
  • Table 13.15 IOV-2001 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
  • Table 13.16 TILs (CAR-T (Shanghai) Cell Biotechnology): Net Present Value (USD Million)
  • Table 13.17 TILs (CAR-T (Shanghai) Cell Biotechnology): Value Creation Analysis (USD Million)
  • Table 13.18 TILs (Bristol-Myers Squibb): Net Present Value (USD Million)
  • Table 13.19 TILs (Bristol-Myers Squibb): Value Creation Analysis (USD Million)
  • Table 14.1 Leading TIL-based Therapy Developers
  • Table 14.2 Cellectis: Company Profile
  • Table 14.3 Cellular Biomedicine Group: Company Profile
  • Table 14.4 Iovance Biotherapeutics: Company Profile
  • Table 14.5 Lytix Biopharma: Company Profile
  • Table 14.6 Phio Pharmaceuticals: Company Profile
  • Table 17.1 TIL-based Therapies: Distribution by Type of Developer
  • Table 17.2 TIL-based Therapies: Distribution by Phase of Development
  • Table 17.3 TIL-based Therapies: Distribution by Therapeutic Area
  • Table 17.4 TIL-based Therapies: Distribution by Key Target Indications
  • Table 17.5 TIL-based Therapies: Distribution by Source of T-Cells
  • Table 17.6 TIL-based Therapies: Distribution by Route of Administration
  • Table 17.7 TIL-based Therapies: Distribution by Dosing Frequency
  • Table 17.8 TIL-based Therapies: Distribution by Target Patient Segment
  • Table 17.9 TIL-based Therapies: Distribution by Type of Therapy
  • Table 17.10 Most Active Industry Players: Analysis by Number of TIL-based Therapies
  • Table 17.11 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
  • Table 17.12 TIL-based Therapy Developers: Distribution by Year of Establishment
  • Table 17.13 TIL-based Therapy Developers: Distribution by Company Size
  • Table 17.14 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
  • Table 17.15 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
  • Table 17.16 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2017-2022
  • Table 17.17 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2017-2022
  • Table 17.18 Clinical Trial Analysis: Distribution by Trial Status
  • Table 17.19 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
  • Table 17.20 Clinical Trial Analysis: Distribution of Trials by Trial Phase
  • Table 17.21 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Table 17.22 Clinical Trial Analysis: Distribution by Target Patient Segment
  • Table 17.23 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 17.24 Clinical Trial Analysis: Distribution by Study Design
  • Table 17.25 Most Active Industry Players: Distribution by Number of Registered Trials
  • Table 17.26 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Table 17.27 Clinical Trial Analysis: Distribution of Trials by Geography
  • Table 17.28 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
  • Table 17.29 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
  • Table 17.30 Clinical Trial Analysis: Distribution of Enrolled Patient Population by

Geography

  • Table 17.31 KOL Analysis: Distribution by Type of Organization
  • Table 17.32 KOL Analysis: Distribution by Affiliated Organization
  • Table 17.33 KOL Analysis: Distribution by Qualification
  • Table 17.34 KOL Analysis: Distribution by Geography
  • Table 17.35 Most Prominent KOLs: Distribution by RA Score
  • Table 17.36 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
  • Table 17.37 LN-144: Estimated Sales Revenues
  • Table 17.38 LN-145: Estimated Sales Revenues
  • Table 17.39 ITIL-168: Estimated Sales Revenues
  • Table 17.40 LTX-315: Estimated Sales Revenues
  • Table 17.41 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
  • Table 17.42 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 17.43 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
  • Table 17.44 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 17.45 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
  • Table 17.46 Most Popular Products: Distribution by Number of Partnerships
  • Table 17.47 Most Active Industry Players: Distribution by Number of Partnerships
  • Table 17.48 Most Active Non-Industry Players: Distribution by Number of Partnerships
  • Table 17.49 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
  • Table 17.50 Partnerships and Collaborations: Distribution of International and Local Deals
  • Table 17.51 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018-2022
  • Table 17.52 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018-2022 (USD Million)
  • Table 17.53 Funding and Investment Analysis: Distribution of Instances by Type of Funding
  • Table 17.54 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
  • Table 17.55 Funding and Investment Analysis: Distribution by Type of Investor
  • Table 17.56 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
  • Table 17.57 Most Active Players: Distribution by Number of Instances
  • Table 17.58 Most Active Players: Distribution by Amount Invested (USD Million)
  • Table 17.59 Funding and Investment Analysis: Distribution of Amount Invested by Geography
  • Table 17.60 Patent Analysis: Distribution by Type of Patent
  • Table 17.61 Patent Analysis: Cumulative Distribution by Patent Publication Year
  • Table 17.62 Patent Analysis: Cumulative Distribution Patent Application Year
  • Table 17.63 Patent Analysis: Cumulative Distribution by Annual Granted Patents
  • Table 17.64 Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
  • Table 17.65 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications
  • Table 17.66 Patent Analysis: Distribution by Geography
  • Table 17.67 Patent Analysis: Distribution by Type of Player
  • Table 17.68 Patent Analysis: Distribution by CPC Symbols
  • Table 17.69 Leading Industry Players: Distribution by Number of Patents
  • Table 17.70 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 17.71 Leading Patent Assignees: Distribution by Number of Patents
  • Table 17.72 Patent Analysis: Distribution by Patent Age
  • Table 17.73 TIL-based Therapies: Patent Valuation Analysis

LIST OF FIGURES

  • Figure 2.1 Executive Summary: Overall Market Landscape
  • Figure 2.2 Executive Summary: Clinical Trial Analysis
  • Figure 2.3 Executive Summary: Partnerships and Collaborations
  • Figure 2.4 Executive Summary: Funding and Investment Analysis
  • Figure 2.5 Executive Summary: Patent Analysis
  • Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 3.1 Pillars of Cancer Therapy
  • Figure 3.2 Differences between Active and Passive Immunotherapies
  • Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
  • Figure 3.4 Strategies Employed for the Redirection of T-Cells
  • Figure 3.5 T-Cell Manufacturing: General Procedure
  • Figure 3.6 TIL-based Therapies: Development Process
  • Figure 4.1 TIL-based Therapies: Distribution by Type of Developer
  • Figure 4.2 TIL-based Therapies: Distribution by Phase of Development
  • Figure 4.3 TIL-based Therapies: Distribution by Therapeutic Area
  • Figure 4.4 TIL-based Therapies: Distribution by Key Target Indications
  • Figure 4.5 TIL-based Therapies: Distribution by Source of T-Cells
  • Figure 4.6 TIL-based Therapies: Distribution by Route of Administration
  • Figure 4.7 TIL-based Therapies: Distribution by Dosing Frequency
  • Figure 4.8 TIL-based Therapies: Distribution by Target Patient Segment
  • Figure 4.9 TIL-based Therapies: Distribution by Type of Therapy
  • Figure 4.10 Most Active Industry Players: Distribution by Number of TIL-based Therapies
  • Figure 4.11 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
  • Figure 4.12 TIL-based Therapy Developers: Distribution by Year of Establishment
  • Figure 4.13 TIL-based Therapy Developers: Distribution by Company Size
  • Figure 4.14 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
  • Figure 4.15 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
  • Figure 5.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 5.2 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2017-2022
  • Figure 5.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2017-2022
  • Figure 5.4 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 5.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2017-2022
  • Figure 5.6 Clinical Trial Analysis: Distribution of Trials by Trial Phase
  • Figure 5.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Figure 5.8 Clinical Trial Analysis: Distribution by Target Patient Segment
  • Figure 5.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 5.10 Clinical Trial Analysis: Distribution by Study Design
  • Figure 5.11 Most Active Industry Players: Distribution by Number of Registered Trials
  • Figure 5.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Figure 5.13 Word Cloud Analysis: Emerging Focus Areas
  • Figure 5.14 Clinical Trial Analysis: Distribution of Trials by Geography
  • Figure 5.15 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
  • Figure 5.16 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
  • Figure 5.17 Clinical Trial Analysis: Distribution of Enrolled Patient Population by

Geography

  • Figure 6.1 KOL Analysis: Distribution by Type of Organization
  • Figure 6.2 KOL Analysis: Distribution by Affiliated Organization
  • Figure 6.3 KOL Analysis: Distribution by Qualification
  • Figure 6.4 KOL Analysis: Distribution by Geography
  • Figure 6.5 TIL-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
  • Figure 6.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
  • Figure 6.7 Most Prominent KOLs: Distribution by RA Score
  • Figure 6.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
  • Figure 6.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
  • Figure 7.1 LN-144: Estimated Sales Revenues
  • Figure 7.2 LN-145: Estimated Sales Revenues
  • Figure 7.3 ITIL-168: Estimated Sales Revenues
  • Figure 7.4 LTX-315: Estimated Sales Revenues
  • Figure 8.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
  • Figure 8.4 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2015-2022
  • Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 8.6 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
  • Figure 8.7 Most Popular Products: Distribution by Number of Partnerships
  • Figure 8.8 Most Active Industry Players: Distribution by Number of Partnerships
  • Figure 8.9 Most Active Non-Industry Players: Distribution by Number of Partnerships
  • Figure 8.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 8.11 Partnerships and Collaborations: International and Local Deals
  • Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Distribution of Instances, Pre-2018-2022
  • Figure 9.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, Pre-2018-2022 (USD Million)
  • Figure 9.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
  • Figure 9.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 9.5 Funding and Investment Analysis: Distribution by Type of Investor
  • Figure 9.6 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
  • Figure 9.7 Most Active Players: Distribution by Number of Instances
  • Figure 9.8 Most Active Players: Distribution by Amount Invested (USD Million)
  • Figure 9.9 Funding and Investment Analysis: Distribution of Amount Invested by Geography
  • Figure 10.1 Patent Analysis: Distribution by Type of Patent
  • Figure 10.2 Patent Analysis: Cumulative Distribution by Patent Publication Year
  • Figure 10.3 Patent Analysis: Cumulative Distribution by Patent Application Year
  • Figure 10.4 Patent Analysis: Cumulative Year-wise Distribution of Granted Patents
  • Figure 10.5 Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
  • Figure 10.6 Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents
  • Figure 10.7 Patent Analysis: Distribution by Geography
  • Figure 10.8 Patent Analysis: Distribution by Type of Player
  • Figure 10.9 Patent Analysis: Distribution by CPC Symbols
  • Figure 10.10 Word Cloud Analysis: Emerging Focus Areas
  • Figure 10.11 Leading Industry Players: Distribution by Number of Patents
  • Figure 10.12 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 10.13 Leading Patent Assignees: Distribution by Number of Patents
  • Figure 10.14 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
  • Figure 10.15 Patent Analysis: Distribution by Patent Age
  • Figure 10.16 TIL-based Cell Therapies: Patent Valuation Analysis
  • Figure 11.1 Steps for Manufacturing Cell Therapies
  • Figure 11.2 Centralized Manufacturing: Process Model
  • Figure 11.3 Decentralized Manufacturing: Process Model
  • Figure 11.4 Cell Therapy Manufacturing: Types of Manufacturers
  • Figure 11.5 Cell Therapy: Challenges and Drivers
  • Figure 11.6 Cell Therapies: Potency as Critical Quality Attribute
  • Figure 11.7 Cell Therapy Manufacturing: Supply Chain Model
  • Figure 11.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
  • Figure 12.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
  • Figure 13.1 Global TIL-based Therapies Market, 2022-2035 (USD Billion)
  • Figure 13.2 TIL-based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
  • Figure 13.3 TIL-based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
  • Figure 13.4 TIL-based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
  • Figure 13.5 Lifileucel / LN-144 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
  • Figure 13.6 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
  • Figure 13.7 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2035 (USD Million)
  • Figure 13.8 TILs (Prometheus Laboratories) Sales Forecast, till 2035 (USD Million)
  • Figure 13.9 Donor Lymphocyte Infusion (Incyte) Sales Forecast, till 2035 (USD Million)
  • Figure 13.10 ITIL-168 (Instil Bio) Sales Forecast, till 2035 (USD Million)
  • Figure 13.11 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
  • Figure 13.12 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, till 2035 (USD Million)
  • Figure 13.13 TILs (Bristol-Myers Squibb) Sales Forecast, till 2035 (USD Million)
  • Figure 15.1 Concluding Remarks: Market Landscape
  • Figure 15.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 15.3 Concluding Remarks: Key Opinion Leaders
  • Figure 15.4 Concluding Remarks: Partnerships & Collaborations
  • Figure 15.5 Concluding Remarks: Funding and Investment Analysis
  • Figure 15.6 Concluding Remarks: Patent Analysis
  • Figure 15.7 Concluding Remarks: Market Forecast